Atai Life Sciences is a clinical-stage biopharmaceutical company developing novel therapeutics for mental health conditions. They are advancing psychedelic and non-psychedelic compounds, including DMT, MDMA, and psilocin, to offer rapid-acting and durable relief for patients with treatment-resistant depression, social anxiety disorder, and cognitive impairment.

Beckley Psytech is developing a novel synthetic intranasal formulation of 5-MeO-DMT benzoate, designed to provide rapid and lasting treatment effects for mental health conditions such as Treatment Resistant Depression and Alcohol Use Disorder. The company addresses the significant unmet need for effective and accessible mental health treatments by leveraging next-generation psychedelic compounds that can be administered in a short clinic visit.

Ceretype Neuromedicine offers a next-generation fMRI brain biomarker platform that provides precise, millimeter-scale mapping of brain activity to enhance drug development and patient care in neuropsychiatry. By delivering actionable insights into brain circuitry, Ceretype addresses the lack of biological evidence in psychiatric treatment, enabling more effective and personalized therapeutic solutions.

Lykos Therapeutics develops investigational psychedelic compounds and provides therapist training programs to enhance treatment options for mental health conditions, particularly PTSD. By focusing on evidence-based research, the company aims to create safe and effective prescription psychedelic therapies that can be integrated into the healthcare system.

Maya Health is a software platform that tracks and measures health outcomes through data analytics and visualization tools. It provides clients with actionable insights to improve their health management and decision-making processes.

Tactogen is a biopharma startup developing empathogen medicines using machine learning and targeted assays to identify novel small molecules that improve mental health outcomes. The company focuses on creating safer and more effective treatments for anxiety, depression, and stress-related disorders, aiming to enhance accessibility to mental wellness solutions.

Tetra Pharm Technologies develops pharmaceutical drugs targeting the central nervous system and immune system to treat neuropathic pain and mental health disorders. The company focuses on improving patient quality of life through scientifically validated therapies that address the unmet needs in neurological and psychological health.